Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof

a technology of bi-specific complexes and antibodies, applied in the field of immunopharmacology, can solve the problems of ineffective newly developed immunopharmacological treatments targeting a single antibody (e.g. ige), t cell cytokine (e.g. anti-il-5) or several transcription factors (e.g. stat-6, -1), and achieves the effect of inhibiting eosinophil activity and inhibiting mast cell activity

Inactive Publication Date: 2012-03-13
DIMES - DIPARTIMENTO DO MEDICINA SPERIMENTALE - UNIV DEGLI STUDI DI GENOVA 40 +1
View PDF0 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Knowledge, however, has not yet yielded efficacious therapeutic means.
In addition, newly developed immunopharmacological treatments targeting a single antibody (e.g. IgE), T cell cytokine (e.g. anti-IL-5) or several transcription factors (e.g. STAT-6, GATA-3 or FOG-1) have not proven efficient as yet.
Notably, while anti-IgE therapy is now approved for the treatment of asthma, it only induces a modest improvement.
The eosinophil basic proteins were found to be highly toxic in vitro to respiratory epithelial cells, at concentrations detected in biological fluid from patients with asthma.
However, the role of these receptors in promoting eosinophil activation in vivo (especially in the setting of chronic allergic airway inflammation) is not known.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof
  • Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof
  • Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

CBMC Express IRp60

[0188]In order to investigate the expression pattern of inhibitory receptors on human mast cells, a screening approach was employed, using a large panel of mAbs recognizing various inhibitory receptors. As shown in FIG. 1A, FACS analysis revealed that CBMC express high levels of IRp60, but not LIR1 / ILT2, LIR3 / ILT5, p58.1, p58.2, p70, p140 or NKG2A / CD94 [n=10]. One out of the ten donors expressed CD94 but not NKG2A. In addition, CBMC were positively stained for FcγRIIB, a known inhibitory receptor [data not shown].

[0189]In order to evaluate whether mature tissue mast cells express IRp60, HLMC were stained for IRp60 expression. As shown in FIG. 1B, HLMC express significant levels of IRp60 as well [n=3]. Next these cells were screened with different mAbs recognizing IRp60 [i.e. P192 and E59] to examine whether this expression pattern is antibody dependent. Both antibodies recognized similar levels of IRp60 on the surface of CBMC and HLMC [n=3.5 respectively, data not ...

example 2

Eosinophil Derived MBP Down-Regulates IRp60 Expression on CBMC

[0190]The inventors next investigated the capability of various mediators, found in the allergic inflammatory milieu, to modulate IRp60 expression on CBMC. For this, CBMC were cultured for various time points in the presence of TNF-α, IL-3, IL-4, monomeric IgE, NGF and eosinophil derived MBP. With the exception of MBP, none of the mediators significantly influenced IRp60 expression. As shown in FIG. 2, MBP induced a decrease in the expression level of IRp60 starting at 12 hours reaching a significant effect after 24 hours [n=3, p<0.01]. The effect of MBP was charge-independent since poly-L-arginine at an equimolar range [25-100 nM] did not affect IRp60 expression.

example 3

IRp60 Cross-Linking Inhibits IgE-Dependent Mediator Release from CBMC

[0191]The expression of IRp60 on the surface of CBMC suggests that their responses may be regulated by this receptor. To evaluate the ability of IRp60 to inhibit CBMC degranulation, CBMC were sensitized with IgE and triggered to degranulate using an anti-IgE antibody or compound 48 / 80 in an anti-IRp60 coated plate. As shown in FIGS. 3A and 3B, cross-linking of IRp60 strongly and significantly inhibited IgE-mediated release of β-hexosaminidase[47.61±2.00% vs. 11.71±1.12% with anti-IRp60, p<0.001], tryptase [60.90±7.35% vs. 14.11±1.45% with anti-IRp60, p<0.001] and IL-4 [8.41±1.19 pg / mL vs. 0.32±0.09 pg / mL with anti-IRp60, p<0.001]. Interestingly, as shown in FIG. 3C, cross-linking of IRp60 did not inhibit compound 48 / 80-mediated release of β-hexosaminidase, tryptase and IL-4 [data not shown].

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
pHaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

Disclosed are bi-specific complexes aimed at inhibiting mast cells, eosinophils and / or basophils, and thus, at inhibiting allergy-type reactions. In particular, said complexes are best exemplified by bi-specific antibodies, which bind to two targets present in the same cell. One target is the inhibitory receptor IRp60. The second target is a cell-specific activator, e.g. IgE, cKIT, FcεRI, IL5R or CCR3. Binding of the bi-specific antibody to its targets results in the induction of an inhibitory pathway, through the inhibition of the signaling from the activator. Compositions and uses of the bi-specific complexes are also described.

Description

RELATED APPLICATIONS[0001]This application is a National Phase Application of PCT Patent Application No. PCT / IL2005 / 000358 having an International Filing Date of Mar. 30, 2005, which claims the benefit of U.S. Provisional Patent Application No. 60 / 557,377 filed on Mar. 30, 2004. The contents of the above Applications are all incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to the field of immunopharmacology. More specifically, the present invention refers to a bi-specific molecule which functions as a modulator of allergic inflammation, being both a preventive and therapeutic tool.BACKGROUND OF THE INVENTION[0003]All publications mentioned throughout this application are fully incorporated herein by reference, including all references cited therein.A. Allergic Inflammation[0004]Allergic inflammation is a complex phenomenon, involving various cell types such as inflammatory and structural cells. Mast cells are the well-established initiators ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K39/395A61K39/00A61K47/48C07K16/28C07K16/42
CPCA61K47/48561A61K47/48653C07K16/2803C07K16/4291C07K2317/31A61K47/6849A61K47/6873A61P1/04A61P11/00A61P11/02A61P11/06A61P17/00A61P19/02A61P19/06A61P25/00A61P27/02A61P29/00A61P35/00A61P35/02A61P35/04A61P37/02A61P37/08A61P9/10
Inventor LEVI-SCHAFFER, FRANCESCABACHELET, IDOMUNITZ, ARIELMORETTA, LORENZOMORETTA, ALESSANDRO
Owner DIMES - DIPARTIMENTO DO MEDICINA SPERIMENTALE - UNIV DEGLI STUDI DI GENOVA 40
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap